Global drugmakers consider reduction of Russian range in years to come

More and more global drugmakers operating in Russia are considering suspension sales of at least part of their new range in the local market in the coming years, due to new rules on price regulation that were recently approved by the Russian Ministry of Health and which will take effect in 2020, according to recent statements of producers.

According to some Russian media reports, the newly-approved rules provide an opportunity to the Russian government for the mandatory re-registration of maximum selling prices for drugs from the list of essential, reports The Pharma Letter’s local correspondent.

This has already sparked criticism from drugmakers, including foreign enterprises operating in the Russian pharmaceutical market.